Semzuvolimab

N/A

Report date: 2022/03/01 14:31:24

Base Information

Drug NameSemzuvolimab
Drug Alias NamedB4UB-421mAb-B4
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAnti-CD4
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesUnited Biomedical Inc
China Registration ClassN/A

Develop Information

Active CompaniesUbp Greater China (Shanghai) Co LtdUbi Pharma IncPpd Pharmaceutical Development (Beijing) Co Ltd +[4] 
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)Lianyao (Shanghai) Biological Technology Co Ltd
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A